Beam Therapeutics (NASDAQ:BEAM) Trading 9.3% Higher – Here’s What Happened

Posted by Stanley Muller on Sep 17th, 2026

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report)’s share price was up 9.3% during mid-day trading on Thursday . The company traded as high as $25.50 and last traded at $25.2520. Approximately 551,079 shares changed hands during mid-day trading, a decline of 73% from the average daily volume of 2,059,151 shares. The stock had previously closed at $23.10.

Analysts Set New Price Targets

A number of research firms have recently issued reports on BEAM. Wall Street Zen downgraded shares of Beam Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday. Bank of America reissued a “buy” rating and issued a $47.00 target price on shares of Beam Therapeutics in a report on Wednesday, July 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Beam Therapeutics in a research note on Friday, July 17th. Wedbush reaffirmed an “outperform” rating and set a $65.00 target price on shares of Beam Therapeutics in a report on Wednesday, September 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Beam Therapeutics in a report on Tuesday, August 25th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $49.00.

Check Out Our Latest Analysis on BEAM

Beam Therapeutics Stock Performance

The company has a current ratio of 14.57, a quick ratio of 14.57 and a debt-to-equity ratio of 0.09. The company has a market cap of $2.55 billion, a P/E ratio of -28.76 and a beta of 2.22. The company’s 50-day moving average price is $27.71 and its two-hundred day moving average price is $28.74.

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.07). Beam Therapeutics had a negative net margin of 54.75% and a negative return on equity of 30.71%. The company had revenue of $0.49 million during the quarter, compared to the consensus estimate of $16.37 million. During the same period in the prior year, the company posted ($1.00) EPS. Beam Therapeutics’s quarterly revenue was down 94.2% on a year-over-year basis. As a group, equities analysts forecast that Beam Therapeutics Inc. will post -4.49 earnings per share for the current year.

Insider Activity

In other news, insider Amy Simon sold 16,667 shares of Beam Therapeutics stock in a transaction on Monday, July 27th. The stock was sold at an average price of $25.74, for a total transaction of $429,008.58. Following the transaction, the insider owned 85,696 shares in the company, valued at approximately $2,205,815.04. The trade was a 16.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Fmr Llc sold 251,488 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $35.26, for a total transaction of $8,867,466.88. Following the transaction, the insider directly owned 854,583 shares in the company, valued at $30,132,596.58. The trade was a 22.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 301,527 shares of company stock valued at $10,468,500. Corporate insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Beam Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. bought a new position in Beam Therapeutics during the second quarter valued at approximately $43,000. Hollencrest Capital Management bought a new stake in Beam Therapeutics during the first quarter valued at about $43,000. Nykredit A S bought a new stake in Beam Therapeutics during the 2nd quarter valued at approximately $75,000. Leonteq Securities AG bought a new stake in shares of Beam Therapeutics in the fourth quarter valued at approximately $66,000. Finally, Allworth Financial LP acquired a new stake in Beam Therapeutics in the 2nd quarter worth $88,000. 99.68% of the stock is owned by hedge funds and other institutional investors.

Beam Therapeutics Company Profile

(Get Free Report)

Beam Therapeutics Inc is a biotechnology company focused on developing genetic medicines using its proprietary base-editing technology. Unlike conventional gene-editing approaches that can make double-strand breaks in DNA, base editing is designed to make targeted changes to individual DNA letters, with the goal of treating diseases at their genetic source.

The company is developing both ex vivo and in vivo therapies. Its pipeline has included programs for sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency, glycogen storage disease type Ia and certain cancers.